Cargando…
Epstein–Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement
Although Epstein–Barr virus (EBV) reactivation has long been associated with the pathogenesis of systemic lupus erythematosus (SLE), many aspects of this relationship remain unclear. Our objective was to investigate the association between EBV reactivation and the achievement of SLE remission and lu...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093904/ https://www.ncbi.nlm.nih.gov/pubmed/37047126 http://dx.doi.org/10.3390/ijms24076156 |
_version_ | 1785023708238184448 |
---|---|
author | Miskovic, Rada Cirkovic, Andja Miljanovic, Danijela Jeremic, Ivica Grk, Milka Basaric, Milica Lazarevic, Ivana Stojanovic, Maja Plavsic, Aleksandra Raskovic, Sanvila Banko, Ana |
author_facet | Miskovic, Rada Cirkovic, Andja Miljanovic, Danijela Jeremic, Ivica Grk, Milka Basaric, Milica Lazarevic, Ivana Stojanovic, Maja Plavsic, Aleksandra Raskovic, Sanvila Banko, Ana |
author_sort | Miskovic, Rada |
collection | PubMed |
description | Although Epstein–Barr virus (EBV) reactivation has long been associated with the pathogenesis of systemic lupus erythematosus (SLE), many aspects of this relationship remain unclear. Our objective was to investigate the association between EBV reactivation and the achievement of SLE remission and lupus low disease activity state (LLDAS) over a six-month period. Clinical, laboratory, and virological tests (anti-EBV antibodies and EBV DNA) were performed among 51 patients with the active form of SLE on two occasions six months apart. SLE remission and LLDAS achievement were assessed at the end of the follow-up period. Active EBV infection was detected in 45% of active SLE patients at baseline, and 77% transitioned to latent EBV infection at six months (p < 0.001). Multivariate regression revealed a higher titer of anti-EA(D) IgM-Abs and the presence of anti-EA(D) IgM-Abs as independent predictors of remission and LLDAS in SLE patients with mucocutaneous manifestations (p = 0.042) and rash only (p = 0.023), respectively. Since a higher C3 level was an independent predictor of transition to latent EBV infection (p = 0.027), the estimated cut-off value that could identify active SLE patients who will transition to latent EBV infection after six months was ≥0.780 g/L with a sensitivity of 70.6% and a specificity of 75.0% (AUC = 0.756, p = 0.003). EBV reactivation is common in patients with active SLE, and most of them transition to latent EBV infection after six months. Achieving remission and LLDAS in SLE patients with mucocutaneous manifestations can be predicted by a higher titer, whereas in SLE patients who have only a rash, the presence of anti-EA (D) IgM-Abs was a predictor of remission and LLDAS. |
format | Online Article Text |
id | pubmed-10093904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100939042023-04-13 Epstein–Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement Miskovic, Rada Cirkovic, Andja Miljanovic, Danijela Jeremic, Ivica Grk, Milka Basaric, Milica Lazarevic, Ivana Stojanovic, Maja Plavsic, Aleksandra Raskovic, Sanvila Banko, Ana Int J Mol Sci Article Although Epstein–Barr virus (EBV) reactivation has long been associated with the pathogenesis of systemic lupus erythematosus (SLE), many aspects of this relationship remain unclear. Our objective was to investigate the association between EBV reactivation and the achievement of SLE remission and lupus low disease activity state (LLDAS) over a six-month period. Clinical, laboratory, and virological tests (anti-EBV antibodies and EBV DNA) were performed among 51 patients with the active form of SLE on two occasions six months apart. SLE remission and LLDAS achievement were assessed at the end of the follow-up period. Active EBV infection was detected in 45% of active SLE patients at baseline, and 77% transitioned to latent EBV infection at six months (p < 0.001). Multivariate regression revealed a higher titer of anti-EA(D) IgM-Abs and the presence of anti-EA(D) IgM-Abs as independent predictors of remission and LLDAS in SLE patients with mucocutaneous manifestations (p = 0.042) and rash only (p = 0.023), respectively. Since a higher C3 level was an independent predictor of transition to latent EBV infection (p = 0.027), the estimated cut-off value that could identify active SLE patients who will transition to latent EBV infection after six months was ≥0.780 g/L with a sensitivity of 70.6% and a specificity of 75.0% (AUC = 0.756, p = 0.003). EBV reactivation is common in patients with active SLE, and most of them transition to latent EBV infection after six months. Achieving remission and LLDAS in SLE patients with mucocutaneous manifestations can be predicted by a higher titer, whereas in SLE patients who have only a rash, the presence of anti-EA (D) IgM-Abs was a predictor of remission and LLDAS. MDPI 2023-03-24 /pmc/articles/PMC10093904/ /pubmed/37047126 http://dx.doi.org/10.3390/ijms24076156 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Miskovic, Rada Cirkovic, Andja Miljanovic, Danijela Jeremic, Ivica Grk, Milka Basaric, Milica Lazarevic, Ivana Stojanovic, Maja Plavsic, Aleksandra Raskovic, Sanvila Banko, Ana Epstein–Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement |
title | Epstein–Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement |
title_full | Epstein–Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement |
title_fullStr | Epstein–Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement |
title_full_unstemmed | Epstein–Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement |
title_short | Epstein–Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement |
title_sort | epstein–barr virus reactivation as a new predictor of achieving remission or lupus low disease activity state in patients with systemic lupus erythematosus with cutaneous involvement |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093904/ https://www.ncbi.nlm.nih.gov/pubmed/37047126 http://dx.doi.org/10.3390/ijms24076156 |
work_keys_str_mv | AT miskovicrada epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT cirkovicandja epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT miljanovicdanijela epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT jeremicivica epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT grkmilka epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT basaricmilica epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT lazarevicivana epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT stojanovicmaja epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT plavsicaleksandra epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT raskovicsanvila epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement AT bankoana epsteinbarrvirusreactivationasanewpredictorofachievingremissionorlupuslowdiseaseactivitystateinpatientswithsystemiclupuserythematosuswithcutaneousinvolvement |